

Date: 02/11/2020

FREEDOM OF INFORMATION REQUEST 015444 - Cancer

This is a follow up email which was previously sent on 25th October 2020 and 16th October 2020. I am researching the incidence and treatment of melanoma and breast cancer. Could you please answer the following four questions for patients treated by your trust?

1. How many patients are currently (past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+ ? -

2. For patients currently (past 3 months) under treatment for melanoma

How many patients are Stage IIIa?

How many patients are Stage III resectable?

How many Stage III patients received a complete resection in the past 3 months?

3. In the past 3 months, how many melanoma patients were treated with the following:

Bevacizumab

Cobimetinib

Dabrafenib

Dabrafenib AND Trametinib

Dacarbazine

Encorafenib AND Binimetinib

Ipilimumab

Ipilimumab AND Nivolumab

Nivolumab

Pembrolizumab

Trametinib

Vemurafenib

Vemurafenib AND Cobimetinib

Other active systemic anti-cancer therapy

Palliative care only

4. In the past 3 months how many patients were treated with the following for breast cancer?

Abemaciclib + Anastrozole/Exemestane/Letrozole

Abemaciclib + Fulvestrant

Alpelisib + Fulvestrant

Atezolizumab

Bevacizumab

Eribulin

Everolimus + Exemestane

Fulvestrant as a single agent

Gemcitabine + Paclitaxel

Lapatinib

Neratinib

Olaparib

Palbociclib + Anastrozole/Exemestane/Letrozole

Palbociclib + Fulvestrant

Pertuzumab + Trastuzumab + Docetaxel

Ribociclib + Anastrozole/Exemestane/Letrozole

Ribociclib + Fulvestrant

Talazoparib

Transtuzumab + Paclitaxel

Transtuzumab as a single agent

Trastuzumab emtansine

Any other active systemic anti-cancer therapy

The Pharmacy database does not identify drugs against patient disease and the Trust does not clinically code treatment.

Information regarding patient treatment is held within individual patient records and not available from electronic reporting. Patient records are exempt from access under FOI exemption Section 40 Personal Information